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Key messages: 
Sulfasalazine use in anti-PD-1 associated inflammatory arthritis may be associated with more 
frequent hypersensitivity reactions 
 
SIR, Checkpoint blockade has revolutionised the management of several cancers by targeting the 
coinhibitory pathways that down-modulate T cell receptor-mediated T cell activation. However the 
resulting enhanced T cell activation also gives rise to immune-related adverse events (IrAEs). 
Arthritis is an increasingly recognised IrAE following treatment with the licensed antibodies to 
programmed cell death protein-1 (PD-1) and may persist following discontinuation of anti-PD-1.[1]. 
[1] Treatment often consists of corticosteroids, with escalation if required to disease modifying anti-
rheumatic drugs (DMARDs). However uncertainty exists about the possible impact of potent DMARD 
therapy on durability of cancer response with some oncologists reluctant to consider use of 
methotrexate.[2]  
Sulfasalazine combines salicylic acid with the anti-microbial sulfapyridine and has been suggested as 
one possible therapy for IrAE.[1, 2] Sulfasalazine can cause a drug hypersensitivity reaction that 
rarely may be systemic and potentially life-threatening.[3] Importantly such drug hypersensitivity 
reactions are T cell mediated.[4, 5]  
We reviewed all cases of anti-PD-1 associated inflammatory arthritis treated with sulfasalazine at 
our centre. Patient characteristics for the four patients are presented in Table 1. All had metastatic 
melanoma treated with the anti-PD-1 antibody pembrolizumab and three had had prior checkpoint 
blockade with the anti-CTLA4 antibody ipilimumab. 
In Case 1, the initial management of knee and then ankle monoarthritis was with intraarticular 
steroid but sulfasalazine was introduced after progression to involve both knees and ankles. Ten 
days later, he was admitted with pyrexia (37.7°C) and a widespread erythematous maculopapular 
rash. Blood tests revealed an acute rise in alanine transferase (66 U/L) and C-Reactive Protein (CRP) 
(189 mg/L) and new lymphopenia (0.8 x109/L). He improved with 3 days of intravenous 
methylprednisolone followed by a reducing course of oral prednisolone. Sulfasalazine and 
pembrolizumab were both discontinued.  
In case 2, sulfasalazine was commenced for initial monoarthritis of the knee following only transient 
improvement with intra-articular steroid. Five days after starting sulfasalazine, he was admitted with 
fever (38.5°C) and cough with unremarkable chest radiograph and a raised CRP (78 mg/L). He was 
treated with antibiotics for a presumed infection of unknown origin (PUO). Sulfasalazine was 
suspended for one week and future pembrolizumab infusions were deferred. Eleven days after 
restarting sulfasalazine, he was readmitted with fevers and again treated for presumed PUO and 
sulfasalazine was stopped. A month later, sulfasalazine was restarted but nine days later he was 
admitted with low grade fever, non-productive cough, and raised CRP (170 mg/L). No source of 
infection was identified and he was treated with oral prednisolone and sulfasalazine was stopped. 
Five weeks later, an escalating dose of sulfasalazine was reintroduced, but on reduction in 
prednisolone he developed nausea, diarrhoea, deranged liver function tests (ALT 288 U/L) and raised 
CRP. Sulfasalazine was stopped and his symptoms resolved. 
Case 3 had rash, facial swelling and fever but did not seek medical attention as her symptoms settled 
on stopping sulfasalazine.  
Pembrolizumab was suspended in case 4 due to the development of a symmetrical polyarthritis 
involving the shoulders, knees and hands. Four months after the final pembrolizumab infusion, an 
escalating dose of sulfasalazine was introduced and five weeks later, he was admitted with a five day 
history of profound loose stool successfully treated with high dose steroids. Sulfasalazine was 
discontinued.  
We observed a high proportion of adverse reactions with sulfasalazine in the context of anti-PD-1 
associated inflammatory arthritis and sulfasalazine was discontinued in all cases. Drug 
hypersensitivity reactions are are mediated by drug-reactive T lymphocytes,[5] and the risk may 
increase with higher drug levels, or with alteration in T cell function, as exemplified by the 
association of amoxicillin-clavulanate hypersensitivity with the PTPN22 locus,[6] which encodes a 
regulator of T cell function. It is therefore plausible that inhibition of PD-1 might also increase risk 
and this might also apply to other drugs strongly associated with T cell mediated drug 
hypersensitivity syndromes such as carbamazapine and allopurinol. 
In RA clinical trials the withdrawal rate for sulfasalazine was as high as 25%, but this was mostly due 
to the common side effects of nausea, headache and dizziness, with a drug rash occurring in only 4-
5% and other hypersensitivity manifestations being much rarer.[3] Cutaneous and other IrAEs are 
common with checkpoint blockade, and could give rise to diagnostic uncertainty as illustrated in the 
second of our cases. However the temporal association, not observed in our experience with 
methotrexate, the high prevalence and similarity to the recognised sulfasalazine hypersensitivity 
syndrome, and the reoccurrence upon rechallenge, all point towards a genuine drug association.  
Our fourth case was different and characterised by colitis, but in this case pembrolizumab was 
discontinued four months before sulfasalazine was started.  Colitis is a common IrAE following 
checkpoint blockade, and rare following sulfasalazine, suggesting this to be unrelated. However 
recent data indicate that the gut microbiome can influence emergence of IrAEs following checkpoint 
blockade,[7] and since sulfasalazine has an antibiotic component, we cannot excludean indirect 
association through alteration of faecal flora.[8] 
In conclusion we observed a high proportion of hypersensitivity reactions following use of 
sulfasalazine, and suggest caution in its use to manage anti-PD-1 related inflammatory arthritis.  
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Table 1. Patient characteristics. 
Case Gender Age Previous 
immunotherapy 
Cancer 
Response to 
anti-PD-1 
Initial Joint 
presentation 
Subsequent joint 
presentation 
ANA Months from 
Anti-PD1 to 
start of 
arthritis 
Duration on 
sulfasalazine (days) 
Reason for stopping SSZ Management of  
Adverse event 
1 Male 57 Ipilimumab. 
(Stopped due to 
hypophysitis and 
disease 
progression) 
Stable Monoarthritis Symmetrical 
Oligoarthritis 
(knees and ankles) 
Negative 4 10 fever, erythematous maculopapular rash across the face, 
neck, chest and back, acute rise in ALT and CRP and 
lymphopenia 
Discontinuation 
IV and oral corticosteroid 
2 Male 51 Ipilimumab. 
(Stopped due to 
hypophysitis and 
hepatitis) 
Remission Monoarthritis Symmetrical 
Medium/large joint 
polyarthritis 
Negative 7 a) 5 
b) 11 
c) 9 
d) 21 
(concomitant 
steroid) 
a) fever, cough, raised CRP. 
b) fever, raised CRP. 
c) fever, non-productive cough, raised CRP. 
d) nausea, diarrhoea, raised ALT and CRP 
a) Discontinuation 
b) Discontinuation 
c) Discontinuation and  
oral corticosteroid 
d) Discontinuation and  
oral corticosteroid 
3 Female 50 Nil Slight 
progression 
Monoarthritis Symmetrical 
Polyarthritis 
1:4001 5 10 rash over chest, swelling around eyes and face, profound 
lethargy and fever. 
Discontinuation 
4 Male 77 Ipilimumab. 
(Stopped due to 
progression) 
Remission Symmetrical 
Polyarthritis 
Symmetrical 
Polyarthritis 
Negative 2 35 acute late onset colitis  Discontinuation 
IV and oral corticosteroid 
 
Footnote: All cases were anti-CCP antibody and rheumatoid factor negative. ALT, alanine aminotransferase. CRP, C-reactive protein. 1Predated introduction 
of sulfasalazine. 
